Loading...
ROCO
4736
Market cap387mUSD
Jul 28, Last price  
129.50TWD
Name

Taidoc Technology Corp

Chart & performance

D1W1MN
ROCO:4736 chart
P/E
8.57
P/S
2.94
EPS
15.12
Div yield, %
7.72%
Shrs. gr., 5y
0.76%
Rev. gr., 5y
-6.56%
Revenues
4.20b
-9.41%
2,116,696,0002,102,890,0002,040,194,0002,416,684,0002,304,037,0002,520,879,0002,636,842,0003,148,415,0003,344,896,0004,347,275,0004,138,499,0005,903,527,0006,493,259,0009,626,805,0004,806,830,0004,640,735,0004,204,133,000
Net income
1.44b
+24.43%
400,192,000208,275,000217,164,000161,790,000342,645,000427,667,000445,148,000489,420,000425,207,000876,675,000663,905,0001,521,384,0001,974,988,0003,382,780,0001,017,371,0001,158,768,0001,441,815,000
CFO
985m
P
466,802,00071,499,000360,967,000263,436,000374,737,000586,853,000507,881,000636,008,000521,210,000782,665,0001,087,379,0001,682,342,0001,919,770,0003,209,567,0001,172,085,000-181,365,000985,286,000
Dividend
Sep 04, 202510 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1998 and headquartered in New Taipei City, Taiwan, TaiDoc Technology Corporation develops and globally distributes a wide array of medical devices. Their offerings encompass in vitro diagnostics, such as advanced blood glucose and multi-parameter monitoring systems, point-of-care testing equipment, and lancet devices, alongside specialized veterinary health products like blood glucose, calcium, and ketone meters for animals. The company also manufactures general medical equipment, including nebulizers, thermometers, blood pressure and vital sign monitors, and pulse oximeters. Additionally, TaiDoc provides remote monitoring solutions for telehealth, complete with smartphone applications, and produces COVID-19 antigen rapid test kits. Complementing its product portfolio, the company offers essential services in areas like regulatory guidance, clinical recommendations, engineering support, and manufacturing system development.

Key people

Tai-Cheng Chou
Vice President-R&D Division · since 2012
Tung-Chuan Chan
Deputy General Manager-No. 1 R&D Division, Director, Corporate Governance Officer · since 2025
Hung-Chih Chi
Executive Deputy General Manager-Sales Division, Director · since 2012
Wang-Tou No Pu
Deputy General Manager-Sales Division · since 2012
Chia-Chi Wu
Deputy General Manager-No. 1 R&D Division · since 2012
Chi-Ting Huang
Corporate Governance Officer · since 2025
Chao-Wang Chen
Chairman of the Board, General Manager · since 2025
Lan-Yi Chiu
Independent Director · since 2024
Yu-Ting Kuo
Independent Director · since 2018
Yao-Hua Shao
Independent Director · since 2018
Chao-Rong Yang
Independent Director · since 2024
IPO date
Sep 26, 2008
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT